CoChat
Sign Up
Cited by 225Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTryptophan and brain disorders

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

Open access
Alvarez, Enric, Perez, Victor, Dragheim, Marianne, Loft, Henrik, Artigas, Francesc·2012·The International Journal of Neuropsychopharmacology
DOI 10.1017/s1461145711001027PMC PMC3349292
Open this paper in CoChat — free accountOpen PDF

Abstract

The efficacy, safety, and tolerability of Lu AA21004 vs. placebo using venlafaxine XR as active reference in patients with DSM-IV-TR major depressive disorder (MDD) were evaluated. Lu AA21004 is a novel antidepressant that is a 5-HT3 and 5-HT7 receptor antagonist, 5-HT1A receptor agonist, 5-HT1B receptor partial agonist and inhibitor of the 5-HT transporter in recombinant cell lines. In this 6-wk, multi-site study, 429 patients were randomly assigned (1:1:1:1) to 5 or 10 mg Lu AA21004, placebo or 225 mg venlafaxine XR. All patients had a baseline Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥ 30. The primary efficacy analysis was based on the MADRS total score adjusting for multiplicity using a hierarchical testing procedure starting with the highest dose vs. placebo. Lu AA21004 was statistically significantly superior to placebo (n=105) in mean change from baseline in MADRS total score at week 6 (p<0.0001, last observation carried forward), with a mean treatment difference vs. placebo of 5.9 (5 mg, n=108), and 5.7 (10 mg, n=100) points. Venlafaxine XR (n=112) was also significantly superior to placebo at week 6 (p<0.0001). In total, 30 patients withdrew due to adverse events (AEs)--placebo: four (4%); 5 mg Lu AA21004: three (3%); 10 mg Lu AA21004: seven (7%); and venlafaxine: 16 (14%). The most common AEs were nausea, headache, hyperhidrosis, and dry mouth. No clinically relevant changes over time were seen in the clinical laboratory results, vital signs, weight, or ECG parameters. In this study, treatment with 5 mg and 10 mg Lu AA21004 for 6 wk was efficacious and well tolerated in patients with MDD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s1461145711001027

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow chart of patient disposition. AE, Adverse events, ITT, intention to treat; LoE, lack of efficacy; MADRS, Montgomery–Åsberg Depression Rating Scale; PBO, placebo; Ven 225, venlafaxine XR 225 mg.
Fig. 1 Flow chart of patient disposition. AE, Adverse events, ITT, intention to treat; LoE, lack of efficacy; MADRS, Montgomery–Åsberg Depression Rating Scale; PBO, placebo; Ven 225, venlafaxine XR 225 mg.CC BY-NC-SA · PubMed Central
Fig. 2 Mean change from baseline in Montgomery–Åsberg Depression Rating Scale (MADRS) total scores (ANCOVA, FAS, OC, over time) and LOCF (week 6). * p<0.05, ** p<0.01, *** p<0.001 vs. placebo. FAS, Full-analysis set; LOCF, last observation carried forward; OC, observed cases.
Fig. 2 Mean change from baseline in Montgomery–Åsberg Depression Rating Scale (MADRS) total scores (ANCOVA, FAS, OC, over time) and LOCF (week 6). * p<0.05, ** p<0.01, *** p<0.001 vs. placebo. FAS, Full-analysis set; LOCF, last observation carried forward; OC, observed cases.CC BY-NC-SA · PubMed Central
Fig. 3 Mean change from baseline in Hamilton Rating Scale for Anxiety (HAMA) total scores (ANCOVA, FAS, OC, over time) and LOCF (week 6). * p<0.05, ** p<0.01, *** p<0.001 vs. placebo. FAS, Full-analysis set; LOCF, last observation carried forward; OC, observed cases. Some patients were excluded due to the use of a non-validated scale in France.
Fig. 3 Mean change from baseline in Hamilton Rating Scale for Anxiety (HAMA) total scores (ANCOVA, FAS, OC, over time) and LOCF (week 6). * p<0.05, ** p<0.01, *** p<0.001 vs. placebo. FAS, Full-analysis set; LOCF, last observation carried forward; OC, observed cases. Some patients were excluded due to the use of a non-validated scale in France.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 225

Related

See all

Metadata

Authors
Alvarez, E., Perez, V., Dragheim, M., Loft, H., & Artigas, F.
Affiliations
  • Lundbeck (Denmark) (DK)
  • Consejo Superior de Investigaciones Científicas (ES)
Corresponding author
Dragheim, Marianne
ORCID
Artigas, Francesc
Venue
The International Journal of Neuropsychopharmacology
Publisher
Oxford University Press (OUP)
Published
2011-07-18
Volume
15
Issue
05
Pages
589-600
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
DOI
10.1017/s1461145711001027
PMC
PMC3349292
OpenAlex
W2048026164
Cited by
225
References
31
Citations by year
2026: 4 · 2025: 7 · 2024: 14 · 2023: 9 · 2022: 13 · 2021: 11 · 2020: 9 · 2019: 15 · 2018: 13 · 2017: 17 · 2016: 20 · 2015: 33 · 2014: 27 · 2013: 19 · 2012: 11
FWCI
13.82
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, other-oa)
Funders
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Servier
  • H. Lundbeck A/S
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
vortioxetine, major depressive disorder, antidepressant efficacy, 5-HT3 receptor antagonists, 5-HT7 receptor antagonists, 5-HT1A receptor agonist, adverse events, drug tolerability
MeSH terms
Venlafaxine Hydrochloride, Vortioxetine, Adult, Cyclohexanols, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Piperazines, Placebos, Psychiatric Status Rating Scales, Sulfides, Treatment Outcome, Antidepressive Agents, Second-Generation, Diagnostic and Statistical Manual of Mental Disorders, Receptor, Serotonin, 5-HT1A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review